

Non-genomic effects of the Pregnane X Receptor negatively regulate platelet functions, thrombosis and haemostasis

Article

Accepted Version

Flora, G., Sahli, K., Sasikumar, P., Holbrook, L., Stainer, A., Alouda, S., Crescente, M., Sage, T., Unsworth, A. and Gibbins, J. (2019) Non-genomic effects of the Pregnane X Receptor negatively regulate platelet functions, thrombosis and haemostasis. *Scientific Reports*, 9. 17210. ISSN 2045-2322 doi: <https://doi.org/10.1038/s41598-019-53218-x> (In Press) Available at <http://centaur.reading.ac.uk/87042/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1038/s41598-019-53218-x>

Publisher: Nature Publishing Group

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other

copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Non-genomic effects of the Pregnane X Receptor negatively regulate platelet functions, thrombosis and haemostasis

Gagan D. Flora^{† 1, 2}, Khaled A. Sahli^{† 1}, Parvathy Sasikumar^{1,3}, Lisa-Marie Holbrook^{1,4}, Alexander R. Stainer¹, Sarah K. Alouda¹, Marilena Crescente^{1,5}, Tanya Sage¹, Amanda J. Unsworth^{1,6} and Jonathan M. Gibbins¹

¹Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, UK

²Department of Internal Medicine, University of Iowa, Iowa City, IA, USA

³Centre for Haematology, Imperial College London, London, UK

⁴School of Cardiovascular Medicine and Sciences, King's College London, London, UK

⁵Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

⁶School of Healthcare Science, Manchester Metropolitan University, Manchester, UK

[†]*Contributed equally*

Address for correspondence:

Prof. Jonathan Gibbins, PhD
Institute for Cardiovascular and Metabolic Research
School of Biological Sciences
University of Reading
Reading, UK
RG66AS
e-mail: j.m.gibbins@reading.ac.uk

Key words: Platelets, nuclear receptor, thrombosis, glycoprotein VI, Src family kinases

Abstract

The pregnane X receptor (PXR) is a nuclear receptor (NR), involved in the detoxification of xenobiotic compounds. Recently, its presence was reported in the human vasculature and its ligands were proposed to exhibit anti-atherosclerotic effects. Since platelets contribute towards the development of atherosclerosis and possess numerous NRs, we investigated the expression of PXR in platelets along with the ability of its ligands to modulate platelet activation. The expression of PXR in human platelets was confirmed using immunoprecipitation analysis. Treatment with PXR ligands was found to inhibit platelet functions stimulated by a range of agonists, with platelet aggregation, granule secretion, adhesion and spreading on fibrinogen all attenuated along with a reduction in thrombus formation (both *in vitro* and *in vivo*). The effects of PXR ligands were observed in a species-specific manner, and the human-specific ligand, SR12813, was observed to attenuate thrombus formation *in vivo* in humanised PXR transgenic mice. PXR ligand-mediated inhibition of platelet function was found to be associated with the inhibition of Src-family kinases (SFKs). This study identifies acute, non-genomic regulatory effects of PXR ligands on platelet function and thrombus formation. In combination with the emerging anti-atherosclerotic properties of PXR ligands, these anti-thrombotic effects may provide additional cardio-protective benefits.

Introduction

Nuclear receptors (NRs) are well characterised for their genomic functions (transcriptional regulation), however, less is known about their non-genomic roles. Several NRs (such as LXR, PPAR $\alpha/\beta/\gamma$, RXR, RAR and FXR) have been identified in platelets, which upon ligation regulate platelet activity, thrombosis and haemostasis through a variety of mechanisms in a non-genomic manner¹⁻⁷. The pregnane X receptor (PXR) forms a heterodimer with retinoid X receptor (RXR)⁸ and functions as a sensor, activated by xenobiotic and toxic endogenous compounds, leading to their metabolism and elimination through the upregulation of cytochrome P450 enzymes. PXR is predominantly expressed in liver and intestines⁹ and unlike other NRs, displays a large and flexible ligand-binding domain (LBD) that enables its binding with a diverse array of ligands that includes bile acids, pharmaceutical substrates, herbal medicines, environmental pollutants, and endobiotics¹⁰. Additionally, the LBD of PXR shows variation in amino acid sequence amongst different species¹¹. Therefore, inter-species differences in the ligands that activate PXR have been reported. Consequently, human PXR is activated by ligands such as SR12813 and rifampicin, whilst they do not affect mouse PXR. Similarly, the PXR ligand, pregnenolone 16 α -carbonitrile (PCN), is highly specific to rodents only^{12,13}.

Increasing evidence identifies PXR to act as a potential therapeutic target for the treatment of a variety of patho-physiologies¹⁴. PXR ligands have demonstrated anti-atherosclerotic effects via increased cholesterol clearance and HDL production in a mouse model of atherosclerosis¹⁵⁻¹⁷. Recently, PXR was reported to be expressed in the human vasculature (blood vessels, aortic endothelial and smooth muscle cells), where it functions to detoxify circulating toxins and avert vascular damage by upregulating CYP 3A, 2B and 2C activity¹⁸.

Here, we report the presence of PXR in human platelets. Treatment of platelets with PXR ligands (SR12813 or rifampicin) attenuated platelet functions and thrombus formation (*in vitro* and *in vivo*) through a mechanism that is associated with the down-regulation of Src-family kinase (SFKs) signalling.

Materials and Methods

Reagents. Bovine thrombin, rifampicin and 5-Pregnen-3 β -ol-20-one-16 α -carbonitrile (PCN) were purchased from Sigma-Aldrich. Collagen was obtained from Nycomed. CRP-XL was from Professor R. Farndale (University of Cambridge). SR12813 was from Abcam (Cambridge, UK). Primary polyclonal anti-PXR (sc25381), monoclonal anti-RXR $\alpha/\beta/\gamma$ (sc46659), 14-3-3 ζ (sc-293415) and actin (sc-1615) antibodies were from SantaCruz. Monoclonal anti-PXR (ab41930), primary phospho anti-Lyn (Y396) (ab226778), Syk (Y525/526) (ab58575) and LAT (Y200) (ab68139) antibodies were from Abcam. Primary phospho anti-Src (Y418) (#44-660G) was from ThermoFisher Scientific. Primary phospho anti-PLC γ 2 (Y1217) (#3871), VASP (S157 and S239) (#3111 and #3114) and PKC (#2261) were purchased from Cell Signalling Technologies. Anti-phospho-Tyr 4G10 (#05-321) antibody was from Millipore. Fluorophore conjugated secondary antibodies, Fura-2AM and Alexa-488 conjugated phalloidin were from Life Technologies. PE-Cy5 anti-CD62P antibody was from BD Biosciences. FITC-labelled anti-fibrinogen was from Dako. All other reagents were from previously described sources^{5,6}. Humanised PXR transgenic mice [C57BL/6-Nr1i2^{tm1(NR112)Arte}] were purchased from Taconic Biosciences (Denmark) and bred under licence at the bioresource unit of the University of Reading.

Human blood collection. Blood was collected with approval by the University of Reading Research Ethics Committee, and in accordance with the Declaration of

Helsinki. Human blood was collected in 3.8% (v/v) citrate by venepuncture from aspirin free, healthy volunteers after obtaining their informed consent. Detailed method is available in the supplementary information. All methods performed in the study were carried out in accordance with the University of Reading guidelines and regulations concerning ethical approval, health and safety, the use of animals in experimentation and research quality assurance. Experimental protocols were approved by the University of Reading Research Ethics Committee and the Animal Welfare Ethical Review Board. Experiments using animals were approved and performed in accordance with a licence issued by the UK Home Office

Platelet preparation, aggregation and dense granule secretion assays. Platelet aggregation and dense granule secretion in washed platelets was determined using lumiaggregometry by measuring changes in optical density and ATP release, respectively. Detailed method is available in the supplementary information.

Immunofluorescence microscopy. Human (in PRP) stimulated with or without thromboxane A₂ receptor agonist, U46619 (5µM), were left to settle on poly-L-lysine coverslips for 1 hour at 37°C before permeabilisation and blocking (0.2% Triton-X-100, 1% BSA, 2% donkey serum). Coverslips were then incubated with primary antibodies (PXR or RXR and GPIb) overnight (4°C) and washed in PBS before staining with Alexa-fluor conjugated secondary antibodies for 1 hour at room temperature. Platelets were imaged on a Nikon A1-R confocal microscope (100X magnification oil immersion lens). Detailed method is available in the supplementary information.

Immunoblotting and immunoprecipitation. Washed platelets (4×10^8 or 8×10^8 cells/ml) were lysed in an equal volume of NP40 buffer (300mM NaCl, 20mM Tris base, 2mM EGTA, 2mM EDTA, 1mM PMSF, 10 μ g/ml aprotinin, 10 μ g/ml leupeptin, 0.7 μ g/ml pepstatin A, 2mM sodium orthovanadate, 2% NP-40, pH 7.3), and proteins of interest were isolated using 1 μ g/mL of appropriate antibodies. Detailed method is available in the supplementary information. Immunoblotting was performed using standard techniques as described in the supplementary information. Levels of phosphorylated proteins were detected using fluorophore-conjugated secondary antibodies and visualised using a Typhoon FLA 9500 (GE healthcare) and quantified using Image Quant software version 8.1 (GE healthcare). Protein loading was assessed through reprobing for actin or 14-3-3 ζ .

Fibrinogen binding and alpha granule secretion. Activation of the integrin α IIb β 3 and alpha-granule secretion were measured by measuring levels of fibrinogen binding and P-selectin exposure on the platelet surface by flow cytometry using FITC-conjugated anti-fibrinogen and PE/Cy5-labelled anti-CD62P antibody, respectively. Using a BD Accuri C6 flow cytometer, 10,000 events were analysed using the CFlow Sampler software. Detailed methods for both are available in the supplementary information.

Calcium mobilisation. PRP was loaded with Fura-2 AM (2 μ M) for 1h at 30°C and then washed platelets were prepared. Fura-2AM-loaded platelets were incubated with PXR ligands or vehicle prior to their activation. The ratio of emission values (excitation at 340/380 nm) was recorded using a NOVOstar plate reader (BMG Labtech) and converted to calcium concentration. Detailed method is available in the supplementary information.

Platelet spreading and clot retraction. Washed human platelets (2×10^7 cells/ml) treated with or without PXR ligands were exposed to fibrinogen or collagen (100 μ g/ml) coated coverslips for 45 minutes. Adhered platelets were fixed using 2% (v/v) paraformaldehyde and permeabilised with 0.2% (v/v) Triton-X-100. Thereafter, platelets were stained using Alexa488-conjugated phalloidin. Adherent platelets were imaged on a Nikon A1-R confocal microscope (100X magnification oil immersion lens). The number of platelets in different stages of spreading were obtained by counting, for each sample, the number of platelets in 5 randomly chosen fields of view. Clot retraction was studied in thrombin (1 U/mL) stimulated PRP treated with or without PXR ligands for a period of 1 hour (37°C). Clot weight was measured as a marker of clot retraction. Detailed methods are available in the supplementary information.

Thrombus formation *in vitro*. Human or mouse blood fluorescently labelled with lipophilic dye DIOC₆ was pre-incubated with vehicle or PXR ligands and perfused over a collagen-coated (100 μ g/ml) microfluidic biochip (Cellix) at an arterial shear rate (20 dyn/cm²). Images of thrombi were obtained using a using Nikon A1-R Confocal microscope (20X objective) and fluorescence intensity was calculated. Detailed method is available in the supplementary information.

Thrombus formation *in vivo* and tail bleeding assay. Thrombosis in humanised PXR transgenic mice (hPXR) treated with SR12813 or vehicle that were administered intravenously was assayed following laser-induced injury by intravital microscopy. After laser-induced injury of the inner wall of cremaster muscle arterioles, accumulation of platelets was assessed. Fluorescence and bright-field images were recorded using an Olympus BX61W microscope with a 60X/1.0 NA water immersion objective and a high-

speed camera. Data was analysed using Slidebook5 software (Intelligent Imaging Innovations). Tail bleeding experiments following removal of the tail-tip were performed on 20–25g hPXR mice, anesthetized with ketamine (100mg/kg) and xylazine (10mg/kg) injected intraperitoneally. Detailed methods are available in the supplementary information.

Statistical analysis. Data were analysed using ANOVA with Bonferroni post-test as indicated, or where appropriate by t-test. The Mann-Whitney U test was used to analyse tail bleeding and thrombosis assay. Data represent mean±SD and $P < 0.05$ was considered to be statistically significant. Statistical analysis was performed using GraphPad Prism 7.0 software (California, USA).

Results

PXR is present in human platelets. Initial analysis of platelet lysates for the presence of PXR revealed a weak band of the receptor. Therefore, immunoprecipitation was performed to enrich the sample with PXR to enhance its detection. The protein was immunoprecipitated from platelet lysates using a mouse anti-PXR antibody (targeting amino acids 1-40) and its presence was confirmed by immunoblotting with a rabbit anti-PXR antibody (targeting amino acids 101-260) (Fig. 1A). The sub-cellular localisation of PXR was studied in resting human platelets using immunofluorescence microscopy. The PXR (red stain) was noted to be distributed inside the platelet cytosol (green stain marks platelet surface GPIb) in a punctate arrangement (Fig. 1B). Previously, it has been reported that NRs such as RXR and PPAR γ are secreted from platelets upon their activation¹⁹. This was evaluated for PXR in resting and activated (0.1 U/ml thrombin)

permeabilised platelets using flow cytometry. The level of fluorescence associated with PXR in thrombin-activated platelets was reduced, in comparison with resting platelets, suggesting a reduction in the number of PXR molecules present inside the activated platelets, consistent with release or secretion (Fig. 1C, 1D).

PXR and RXR exists as heterodimers in human platelets. The formation of heterodimers between RXR and other NRs (PPAR's, FXR, PXR, LXR) in nucleated cells is known²⁰ and our previous work suggested the existence of RXR-LXR, RXR-PPAR α and RXR-PPAR γ heterodimers in human platelets⁶. The potential ability for PXR to interact with RXR in platelets was therefore examined. RXR and PXR were found to co-immunoprecipitate in both resting and activated platelets (Fig. 2A). Using immunofluorescence microscopy, a high degree of colocalisation between RXR (red) and PXR (blue) was observed in both resting (Fig. 2B) and U46619-activated (5 μ M) (Fig. 2B) platelets (stained in green for GPIb). A scatter plot demonstrated a clear relationship of fluorescence intensity points for RXR and PXR, clustering proportionally along a straight line (approximately 45 degrees to either axis), indicating a high level of colocalisation in resting and activated platelets (Fig. 2C). In alignment with this, the Pearson's correlation coefficient (PCC), was found to be 0.94 and 0.92 between RXR and PXR in resting and activated platelets, respectively, indicating a strong co-localisation. There was no change in the extent of PXR-RXR colocalization between resting and activated platelets (Fig. 2D).

PXR ligands inhibit platelet aggregation to a range of platelet activators. The effects of two structurally distinct PXR ligands, SR12813 and rifampicin¹⁰ were evaluated on platelet aggregation, stimulated by various platelet activators. To maintain consistency in results, the concentration of each platelet agonist for each donor was optimized to

attain 50% maximal aggregation (EC_{50}) in 5 minutes. Treatment of platelets with SR12813 for 10 minutes reduced platelet aggregation mediated by collagen (EC_{50} : 0.5-0.8 $\mu\text{g}/\text{ml}$) by 27% and 40% at 50 and 100 μM SR12813 (Fig. 3A), respectively, compared to vehicle (DMSO 0.1% v/v). Similar levels of inhibition were observed with rifampicin treatment (Suppl. Fig. 1A). Increasing the incubation period of SR12813 (Fig. 3B) or rifampicin (Suppl. Fig. 1B) to 20 minutes strongly enhanced inhibition against collagen-stimulation, which may reflect the rate of transit of PXR ligands across the plasma membrane. Aggregation mediated by the G protein-coupled receptor (GPCR) agonist thrombin (EC_{50} : 0.03-0.04 U/ml) was also attenuated by SR12813 or rifampicin (10-mins incubation). 50 and 100 μM of SR12813 demonstrated 35% and 42% reduction in aggregation respectively at 3-minute post-activation by thrombin in comparison with 5-minutes interval, which was around 15% and 23%, respectively (Fig. 3C). Similar observations were made with rifampicin (Suppl. Fig. 1C). In addition to this, both the PXR ligands inhibited U46619-mediated platelet aggregation (EC_{50} range: 0.2-0.4 μM) (Suppl. Fig. 1D, 1E) and ADP (EC_{50} range: 5-10 μM) (Suppl. Fig. 1F, 1G), indicating that the effects of PXR ligands are widespread (acting on both GPVI and GPCR-mediated platelet activation) and not restricted to a specific platelet activation pathway.

PXR ligands inhibit integrin $\alpha\text{IIb}\beta\text{3}$ activation and platelet secretion. The affinity upregulation of integrin $\alpha\text{IIb}\beta\text{3}$ following platelet activation is essential for platelet aggregation. Therefore, the effects of PXR ligands on the extent of CRP-XL (EC_{50} : 0.25 $\mu\text{g}/\text{ml}$) or thrombin (EC_{50} : 0.05 U/ml) induced fibrinogen binding to integrin $\alpha\text{IIb}\beta\text{3}$ were evaluated in PRP using flow cytometry. In alignment with reduced aggregation, CRP-XL-induced fibrinogen binding was inhibited by 52% at 100 μM SR12813, in comparison to vehicle-control (DMSO 0.1% v/v) (Fig. 3D). Thrombin-stimulated fibrinogen binding was

also attenuated by 100 μ M SR12813 by 40% (Fig. 3E). Similar effects were demonstrated by rifampicin on CRP-XL or thrombin stimulation (Suppl. Fig. 2A). To investigate the effects of PXR ligands on degranulation, the extent of alpha and dense granules secretion was evaluated by measuring P-selectin exposure on the platelet surface and ATP release, respectively. SR12813 (Fig. 3F, 3G) and rifampicin (100 μ M) (Suppl. Fig. 2B) caused 40% and 30% reduction in CRP-XL (0.25 μ g/ml) or thrombin-stimulated (0.05 U/ml) P-selectin exposure, respectively, compared to vehicle (DMSO 0.1% v/v). ATP release following stimulation by either collagen (1 μ g/ml) or thrombin (0.05 U/ml) was also attenuated following pre-treatment of platelets with SR12813 (Fig. 3H, 3I) or rifampicin (Suppl. Fig. 2C, 2D).

In addition to degranulation, activated platelets synthesise TxA₂ from arachidonic acid through the actions of COX-1 and TxA₂ synthase. TxA₂ synthesis and release activate more platelets at the site of injury, thus, amplifying the aggregation response. SR12813 treatment significantly down-regulated both CRP-XL (1 μ g/ml) or thrombin (0.05 U/ml) evoked TxB₂ (a stable metabolite of TxA₂) production by washed platelets (Fig. 3J, 3K). Higher concentrations of platelet agonists were used to ensure maximum secretion and synthesis of ATP and TxB₂ from activated platelets for effective detection. Consequently, incubation time with PXR ligands was prolonged (20 mins) in these assays.

Collagen-evoked platelet aggregation depends partially on the release of secondary mediators. Since PXR ligands can inhibit aggregation instigated by both ADP and U46619, we investigated whether the inhibitory effects of PXR ligands against collagen-stimulation (10 μ g/ml) are independent of their ability to reduce secondary mediator effects. Given the high concentration of collagen used in this assay, SR12813 (100 μ M) on its own did not affect platelet aggregation (Suppl. Fig. 2E), however, the inhibitory effects

of SR12813 (100 μ M) were found to be additive to the inhibition caused by saturating concentrations of secondary mediator inhibitors; indomethacin (20 μ M; TxA_2 synthesis blocker) and ADP receptor antagonists (1 μ M cangrelor and 100 μ M MRS2179). This indicates that the effects of SR12813 on collagen-mediated platelet aggregation are not solely dependent on its effects on secondary mediators released during activation (Suppl. Fig. 2E).

Species-specific effects and inhibition of thrombus formation in vitro by human and mouse PXR ligands. As mentioned earlier, a dissimilarity exists in the sequence of PXR's LBD between species, with only 76% amino acid sequence similarity in the LBD between human and mouse PXR¹⁰. This results in a high degree of inter-species differences in ligands that activate PXR. This property was explored to assess whether the effects of PXR ligands are likely to be mediated through binding to PXR protein in platelets. Consequently, the effects of human (SR12813) or mouse (PCN) PXR ligands on CRP-XL-stimulated fibrinogen binding in human and mouse platelets were investigated. It was not possible to directly compare the responses of human and mouse platelets as their activation profile is quite different towards the similar concentrations of platelet agonists. For instance, a concentration of 0.25 μ g/ml of CRP-XL was sufficient to activate human platelet samples to study the effects of human PXR ligands, however, this produced a modest effect on mouse platelets. Consequently, the CRP-XL concentration was enhanced to 0.5 μ g/ml for experiments using mouse PRP. In comparison to vehicle-control (DMSO 0.1% v/v), 100 μ M of SR12813 reduced CRP-XL-stimulated (0.25 μ g/ml) fibrinogen binding in human platelets by 50% (Fig. 3D). However, SR12813 did not cause any change in mouse platelet responses stimulated with CRP-XL (0.5 μ g/ml) (Fig. 4A). Similarly, mouse PXR ligand, PCN (100 μ M), inhibited CRP-XL-evoked fibrinogen binding

in mouse platelets by 25% in comparison to vehicle-control (DMSO 0.5% v/v), whereas, no effect was observed in human platelets (Fig. 4B). These findings not only demonstrate species-specific effects of PXR ligand but also provides evidence that the effects of PXR ligands are mediated via PXR in human and mouse platelets.

Given the ability of PXR ligands to regulate numerous aspects of platelet activation, we investigated their implications on thrombus formation *in vitro*. Treatment with SR12813 (100 μ M) for 20-minutes inhibited thrombus development in contrast to vehicle (DMSO 0.1% v/v) (Fig. 4C). Rifampicin (100 μ M) treatment also reduced thrombus formation (Suppl. Fig. 3A). Furthermore, the initial kinetics of thrombus-development in PXR ligand-treated samples were inhibited in comparison to vehicle-control, which might be due to reduced adhesion of platelets to collagen.

The thrombus formation assay was also performed to study the species-specific effects of PXR ligands. In comparison to vehicle (DMSO 0.5% v/v), 20-minutes treatment with mouse PXR ligand, PCN (100 μ M), caused a 50% reduction in thrombus formation in mouse blood (Fig. 4E). In contrast, thrombus formation in PCN (100 μ M) treated human blood was not altered (Fig. 4F). To further confirm the species-specific nature of PXR ligands, the effect of human PXR ligand (SR12813) was evaluated in mouse blood. As discussed previously, SR12813 reduced thrombus formation in human blood (Fig. 4C), but thrombus development in mouse blood treated with SR12813 was similar to vehicle-treated samples (Fig. 4D).

PXR ligands inhibit thrombosis and haemostasis in mice. Given the negative-regulation of thrombus formation *in vitro*, the acute effect of human PXR ligand (SR12813) was evaluated *in vivo*. As explained earlier, PXR ligands exhibit species-

specific responses in platelets; therefore, the effects of SR12813 were studied on humanised PXR transgenic mice (hPXR). These mice lack the endogenous PXR gene, which is replaced with human PXR gene and is reported to be responsive towards human PXR ligands and not to mouse PXR ligand²¹⁻²⁴. Prior to the investigation, the expression levels of integrin $\alpha 2\beta 1$, $\alpha \text{IIb}\beta 3$, GPIb and GPVI (Suppl. Fig. 3B, 3C, 3D, 3E) receptors on hPXR were compared with background C57BL/6 mice and were found to be similar.

The acute effects of PXR ligands on *in vivo* thrombus formation were evaluated by studying laser-induced thrombosis in mouse cremaster muscle arterioles. As shown in Fig. 5A, the initial kinetics of thrombus formation in SR12813 (100 μM) treated mice was similar to vehicle (DMSO 0.1% v/v) (Fig. 5B), however, the overall size of thrombi was substantially reduced by 80% (Fig. 5C). Moreover, maximum fluorescence intensity of thrombus was reduced by 45% in SR12813 treated mice, consistent with the formation of smaller thrombi (Fig. 5D). Together these results suggest PXR ligands elicit anti-thrombotic effects. We cannot exclude the effects of other cell types on thrombosis, although the level of inhibition in the presence of SR12813 was comparable to its ability to attenuate thrombus formation *in vitro*, assays where vasculature or endothelial cells are not present. This suggests that PXR-mediated down-regulation of thrombus formation might be independent of the effects from other vascular cell types.

Given the observed anti-thrombotic properties of PXR ligands, the effect of SR12813 on haemostasis was measured by a tail-bleeding assay performed on hPXR mice. The mean time to cessation of bleeding was prolonged to approximately 500 seconds in mice treated with SR12813, in comparison vehicle-treated mice (275 seconds), demonstrating that acute PXR ligand treatment increases bleeding and impairs haemostasis (Fig. 5E). The tail-bleeding assay takes into account both platelet-function and and the coagulation

processes²⁵⁻²⁷ and therefore, besides the effects of PXR ligands on platelet activation, the effects of PXR ligands on coagulation cannot be excluded.

PXR ligands inhibit outside-in signalling. Binding of fibrinogen to integrin $\alpha\text{IIb}\beta\text{3}$ initiates outside-in signalling in platelets, which facilitates platelet spreading and clot retraction, required for the stability of the thrombus. Given the ability of PXR ligands to inhibit events associated with inside-out signalling such as aggregation, integrin $\alpha\text{IIb}\beta\text{3}$ upregulation and degranulation, their effects on outside-in signalling were also evaluated. In comparison to vehicle, fewer platelets were observed adhered to fibrinogen (in 45 minutes) following 20-minutes treatment with SR12813 (50 or 100 μM) (Fig. 6A). Additionally, SR12813 was also found to hinder platelet spreading with fewer platelets forming lamellipodia and increased numbers of cells remaining at the adhered or filopodial phases (Fig. 6A). Similar observations were noted with rifampicin treatment (Suppl. Fig. 4A). Consistent with this, an increase in clot weight (indicative of reduced clot retraction, a process driven by integrin $\alpha\text{IIb}\beta\text{3}$ outside-in signalling) was observed in samples treated with SR12813 (Fig. 6B) or rifampicin (Suppl. Fig. 4B) after 90 minutes, compared to vehicle-treated samples. These data along with previous findings suggest the ability of PXR ligands to modulate bi-directional signalling transmitted via integrin $\alpha\text{IIb}\beta\text{3}$.

To test whether the reduced adhesion and spreading were restricted to the functions of integrin $\alpha\text{IIb}\beta\text{3}$, similar experiments were performed on collagen (which is dependent on integrin $\alpha\text{2}\beta\text{1}$ and GPVI). Platelet adhesion and spreading on collagen was also found to be inhibited with SR12813 (Fig. 6C) and rifampicin (Suppl. Fig. 4C) treatment. These findings along with observations of reduced thrombus formation (*in vitro*) suggest that

PXR ligand-mediated reduction in thrombus formation might be partly due to the diminished platelet adhesion to collagen.

PXR ligands inhibit GPVI-mediated signalling pathway. Having identified anti-thrombotic effects of PXR ligands, we determined the mechanism by which PXR ligands elicit anti-platelet activity. We and others have previously described the involvement of NRs in the regulation of platelet inhibitory signalling pathways, notably activation of the cGMP/PKG and cAMP/PKA linked pathways^{1,4,6}. To determine whether PXR, which we have shown heterodimerises with RXR (which regulates PKA activity)⁶ acts in a similar manner, VASP S157 and VASP S239, markers of PKA and PKG activity respectively, were determined in PXR ligands treated platelets. Neither of the PXR ligands was found to activate PKA (Suppl. Fig. 5A, 5B) or PKG (Suppl. Fig. 5C, 5D) activity, indicating that PXR negatively regulates platelet function independently of these inhibitory signalling pathways.

Since PXR ligands were observed to attenuate collagen/CRP-XL-mediated platelet activation, their effects on the GPVI-signalling pathway were investigated. Platelets were stimulated for 90 seconds under non-aggregating conditions [EGTA (1mM), indomethacin (20 μ M), cangrelor (1 μ M) and MRS2179 (100 μ M)] to block signalling via secondary mediators and ensure the study of primary GPVI-signalling. Consequently, CRP-XL concentration was increased (1 μ g/ml) to visualise the phosphorylation of GPVI-signalling components by immunoblot analysis⁶. Consistent with our earlier observations, pre-treatment of platelets (20-minutes) with 50 and 100 μ M of SR12813 (Fig. 7A) or rifampicin (Suppl. Fig. 6A) significantly reduced CRP-XL-evoked total tyrosine phosphorylation in comparison to vehicle (DMSO 0.1% v/v). Significant attenuation of

early GPVI-signalling events, specifically phosphorylation of Syk (at its auto-phosphorylation site Y525/526) by SR12813 (Fig. 7B) or rifampicin (Suppl. Fig. 6B) was also observed. Following this, CRP-XL-stimulated phosphorylation of Linker for Activation of T cells (LAT) at site Y200 was also down-regulated by SR128123 (Fig. 7C) or rifampicin (Suppl. Fig. 6C) treatment along with the inhibition of PLC γ 2 phosphorylation level (Fig. 7D) (Suppl. Fig. 6D) at Y1217.

As expected, PLC γ 2-dependent downstream processes such as calcium-mobilisation were inhibited by both SR1813 (Fig. 7E) and rifampicin (Suppl. Fig. 6E) treatment, along with the reduction of protein kinase C (PKC) phosphorylation (Fig. 7F) (Suppl. Fig. 6F), both of which are essential for the regulation of cytoskeletal rearrangement, degranulation and integrin α IIb β 3 upregulation²⁸. Together, these observations highlight a potential role for PXR ligands in regulating GPVI-receptor signalling.

Inhibition of Src family kinases (SFKs) as a general mechanism for PXR function.

Platelet function stimulated by GPVI, integrin α IIb β 3 and GPCRs are all dependent on signalling via SFKs²⁹. The down-regulation of both early and late GPVI signalling events suggested the involvement of specific target elements of PXR ligands in GPVI signalling, facilitating this cascade of inhibition. Given the down-regulation of Syk phosphorylation, these elements are likely to act at a level that is upstream of Syk, such as SFKs. Therefore, the regulation of SFK activity by PXR ligands was monitored. Treatment with SR12813 (Fig. 8A) and rifampicin (Suppl. Fig. 7A) (50 and 100 μ M) reduced CRP-XL-induced autophosphorylation of Src at Y418³⁰ and Lyn at Y396³¹ (Fig. 8B) (Suppl. Fig. 7B), in comparison with vehicle (DMSO 0.1% v/v). To determine whether the regulation of SFKs marks a general mechanism of action for PXR ligands, signalling pathways initiated by

other platelet receptors dependent on SFKs (such as CLEC-2 and integrin α IIb β 3) were examined²⁹.

As was observed with other platelet agonists, SR12813 (Suppl. Fig. 7C) and rifampicin (Suppl. Fig. 7D) were found to attenuate platelet aggregation stimulated by CLEC-2 agonist rhodocytin (100 nM). Consistent with this, SR12813 (Fig. 8C) and rifampicin (supplemental Fig. 7E) were also able to significantly diminish rhodocytin (100 nM) induced Src phosphorylation (Y418). The stimulation time with rhodocytin was enhanced (120 secs) to detect phosphorylation considering the long lag-phase associated with the initiation of rhodocytin-evoked platelet aggregation. To further support a general role for PXR ligand-dependent down-regulation of SFK activity, Src phosphorylation was also found to be attenuated in platelets treated with SR12813 (Fig. 8D), following adhesion to fibrinogen (100 μ g/ml). Interestingly, no alteration in Src phosphorylation was observed in rifampicin-treated samples (supplemental Fig. 7F). This might be attributed to the experimental challenges of examining signalling stimulated by fibrinogen under static conditions. Altogether these findings suggest that PXR ligands potentially mediate their inhibitory effects on platelet function via the down-regulation of SFKs activity.

Discussion

Platelets are vital therapeutic targets for the treatment of cardiovascular diseases including atherothrombosis³². Current treatment includes the usage of anti-platelet drugs/therapies that prevent platelet activation by inhibiting different platelet signalling pathways³³. These treatment regimens are effective, however, numerous side-effects (such as bleeding and drug resistance) limit their successful use³⁴. Therefore, the

development of newer strategies with minimal side-effects is required. NRs expressed in platelets have been proposed to exhibit antithrombotic effects³⁵. In this study, we report the expression of PXR in platelets and the ability of its ligands to regulate platelet function and thrombosis.

Acute effects of PXR ligands were investigated, noting that the principal ligands for this receptor required high concentrations (10-100 μ M for this study) to elicit acute biological effects³⁶. It is reported that the ligands that activate PXR require micromolar concentrations, generally two to three orders of magnitude higher than concentrations found circulating in plasma³⁶ and lower than the concentrations used in this study. Sub-micromolar concentrations of PXR ligands are sufficient to elicit genomic effects through regulation of gene expression in nucleated cells. Notably, the work presented here reveals the non-genomic effects of these ligands in anucleated platelets. Given the likely differences in the mechanism of genomic and non-genomic functions of NRs, including PXR, it is not possible to directly compare features of these responses such as EC₅₀. Indeed, our group has previously shown that NRs (such as PPAR γ , LXR, RXR, and FXR) in platelets regulate non-genomic functions that are distinct from genomic regulation^{2,4-6,35}. Genomic effects of NRs are usually determined via cell-based reporter assays that involve exposing transcription factors (such as PXR) to their ligands for prolonged durations (hours or days)^{37,38}, whereas the time frame in which non-genomic effects are elicited ranges from a few seconds to a few minutes and appears to require acute exposure to higher concentrations of NR ligands³⁹. Further work will be required to establish the molecular basis of PXR and other NRs in platelets.

Treatment of platelets with PXR ligands resulted in attenuation of multiple aspects of platelet activation including aggregation, integrin α IIb β 3 activation and granule

secretion. A trend of inhibition (although non-significant) was observed at low concentrations (10 and 20 μM) of PXR ligands. This is relevant as clinical administration of rifampicin (600mg) to treat tuberculosis can achieve such peak plasma levels⁴⁰⁻⁴². Increasing the acute treatment time of platelets with PXR ligands was found to enhance the anti-platelet effects of PXR ligands and as such further work is needed to determine the effects of chronic exposure to low concentrations of PXR ligands on platelet activity and thrombosis.

In platelets, apart from PXR, RXR also interacts with LXR⁶, PPAR α ⁶ and PPAR γ ^{6,19}, although, the role of such heterodimers in non-genomic functions is unclear and requires further investigation. Platelets possess mRNA, capable of undergoing a minor level of translation⁴³. Recently RAR α was identified to regulate protein synthesis to some extent by its binding to a subset of mRNAs in human platelets⁴⁴. Hence, it is possible that other NRs including PXR (in a bound or unbound state with RXR) may also contribute to some level of protein translation even in the absence of a nucleus^{45,46}. To date, we have found no evidence to indicate the formation of NR homodimers in platelets.

PXR ligands down-regulated CRP-XL-mediated calcium-mobilisation and activation of PKC. This observation coupled with the previously reported abilities of PPAR γ ², RXR⁶, LXR⁵ and FXR⁴ ligands to modulate calcium-mobilisation identifies a potentially common and fundamental role of NR ligands in regulating calcium homeostasis in platelets. In addition to PXR, other NRs such as LXR⁵ and PPAR γ ² have also been identified to regulate the GPVI signalling pathway, whereas RXR⁶, PPAR α ¹, PPAR β ⁴⁷ and FXR⁴ function by modulating cyclic nucleotide signalling in platelets. This suggests that platelet NRs have overlapping and distinct mechanisms of action in platelets³⁵.

The inhibition of CRP-XL-induced downstream signalling events in platelets was identified to be an outcome of reduced phosphorylation of SFKs (Src and Lyn), key regulators of upstream signalling events. Besides GPVI, SFKs regulate signalling downstream of several other platelet receptors that include integrin α IIb β 3 and α 2 β 1, CLEC-2, FcR γ IIA and GPIb-IX-V receptor and therefore play a fundamental role in platelet activation²⁹. SR12813 treatment negatively-regulated Src phosphorylation, proximal to integrin α IIb β 3, which ensures thrombus stability via the regulation of outside-in signalling. The mechanism by which, PXR regulates the phosphorylation of SFKs requires further exploration. Given the ability of NRs such as LXR⁵ and PPAR γ ² to bind with key signalling molecules of the GPVI pathway and modulate signalling, it is possible that PXR follows a similar mechanism and interacts with one or more GPVI signalling components to regulate signalling. However, the interaction of PXR with SFKs, Syk, LAT or PLC γ downstream of GPVI was not observed in this study. There remains a range of other potential points of interaction to explore such as the GPVI/FcR γ complex that might facilitate this effect. Consistent with the inhibition of GPVI signalling, thrombus formation, both *in vitro* and *in vivo* was found to be reduced considerably, which might be a combined outcome of reduced activity of SFKs downstream of GPVI, α 2 β 1, GPIb-V-IX and integrin α IIb β 3. Furthermore, Src phosphorylation was also attenuated by PXR ligands, downstream of CLEC-2, which provides additional evidence that PXR ligands broadly affect the activity of SFKs in multiple signalling pathways and thus elicit their effects.

PXR is naturally promiscuous with its activating ligands representing a diverse array of structurally different compounds. However, this promiscuity is also specific in nature as its activators can structurally differ from non-activators by only a few atoms, suggesting that PXR binds to a diverse but precise array of compounds, a feature referred to as

“directed promiscuity”⁴⁸. In this study, we also devised strategies to rule out non-specific effects of PXR ligands. Firstly, we used two different PXR ligands (SR12813 and rifampicin) that have the highest affinity towards this receptor and are also structurally distinct from each other. In addition to this, PXR ligands demonstrated species-specific responses to PXR ligands. Human or mouse PXR ligands did not affect mouse or human platelet activation (as demonstrated via integrin $\alpha\text{IIb}\beta\text{3}$ activation and *in vitro* thrombus formation assays) respectively, while human PXR ligands significantly inhibited human platelets and mouse PXR ligands reduced mouse platelet activation. This is plausible only when the effects of PXR ligands are mediated via PXR. While systemic knock-out models are ideal to test the specificity of ligands, in many circumstances, deletion of transcription factors can lead to far-reaching effects on cell biogenesis and their functions, due to potential effects on the expression of many proteins. It is for this reason that humanised PXR mice were used in this study. In this study, the use of PXR antagonists was avoided, since most NR antagonists are characterised as such due to their effects on the regulation of gene expression. Since the effects of NR agonists on platelets are mediated by alternative, non-genomic mechanisms, and noting our previous observation that some NR antagonists (e.g. RXR) exert similar effects on platelets to respective receptor agonists⁶, we anticipated that this approach may produce a confusing picture. This reinforced our decision to explore the mode of action of PXR ligands in platelets using a genetic approach in mice.

In summary, our study demonstrates the anti-thrombotic properties of PXR ligands. In addition to the already identified anti-atherosclerotic effects of PXR¹⁵⁻¹⁷, these findings suggest the potential use of PXR as a cardio-protective drug target. PXR ligands were also associated with impaired haemostasis and therefore their potential development into

effective therapeutic agents would require careful balancing of anti-platelet effects and bleeding risk.

References

- 1 Ali, F. Y. *et al.* Antiplatelet actions of statins and fibrates are mediated by PPARs. *Arterioscler Thromb Vasc Biol* **29**, 706-711, doi:10.1161/ATVBAHA.108.183160 (2009).
- 2 Moraes, L. A. *et al.* Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation. *Journal of thrombosis and haemostasis : JTH* **8**, 577-587, doi:10.1111/j.1538-7836.2009.03732.x (2010).
- 3 Moraes, L. A. *et al.* Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. *Blood* **109**, 3741-3744, doi:10.1182/blood-2006-05-022566 (2007).
- 4 Moraes, L. A. *et al.* Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets. *Arterioscler Thromb Vasc Biol* **36**, 2324-2333, doi:10.1161/atvbaha.116.308093 (2016).
- 5 Spyridon, M. *et al.* LXR as a novel antithrombotic target. *Blood* **117**, 5751-5761, doi:10.1182/blood-2010-09-306142 (2011).
- 6 Unsworth, A. J. *et al.* RXR Ligands Negatively Regulate Thrombosis and Hemostasis. *Arterioscler Thromb Vasc Biol* **37**, 812-822, doi:10.1161/atvbaha.117.309207 (2017).
- 7 Unsworth, A. J. *et al.* PPARgamma agonists negatively regulate alphaIIb beta3 integrin outside-in signaling and platelet function through up-regulation of protein kinase A activity. *Journal of thrombosis and haemostasis : JTH* **15**, 356-369, doi:10.1111/jth.13578 (2017).
- 8 Ihunnah, C. A., Jiang, M. & Xie, W. Nuclear Receptor PXR, transcriptional circuits and metabolic relevance. *Biochimica et biophysica acta* **1812**, 956-963, doi:10.1016/j.bbadis.2011.01.014 (2011).
- 9 Ma, X., Idle, J. R. & Gonzalez, F. J. The Pregnane X Receptor: From Bench to Bedside. *Expert opinion on drug metabolism & toxicology* **4**, 895-908, doi:10.1517/17425255.4.7.895 (2008).
- 10 Jones, S. A. *et al.* The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. *Molecular endocrinology (Baltimore, Md.)* **14**, 27-39, doi:10.1210/mend.14.1.0409 (2000).
- 11 Escriva, H., Delaunay, F. & Laudet, V. Ligand binding and nuclear receptor evolution. *BioEssays : news and reviews in molecular, cellular and developmental biology* **22**, 717-727, doi:10.1002/1521-1878(200008)22:8<717::aid-bies5>3.0.co;2-i (2000).
- 12 Timsit, Y. E. & Negishi, M. CAR and PXR: The Xenobiotic-Sensing Receptors. *Steroids* **72**, 231-246, doi:10.1016/j.steroids.2006.12.006 (2007).
- 13 Krasowski, M. D., Yasuda, K., Hagey, L. R. & Schuetz, E. G. Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. *Molecular endocrinology (Baltimore, Md.)* **19**, 1720-1739, doi:10.1210/me.2004-0427 (2005).
- 14 Gao, J. & Xie, W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. *Trends in pharmacological sciences* **33**, 552-558 (2012).
- 15 Li, T., Chen, W. & Chiang, J. Y. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. *Journal of lipid research* **48**, 373-384 (2007).
- 16 de Haan, W. *et al.* PXR agonism decreases plasma HDL levels in ApoE* 3-Leiden. CETP mice. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids* **1791**, 191-197 (2009).
- 17 Zhou, C., King, N., Chen, K. Y. & Breslow, J. L. Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. *J Lipid Res* **50**, 2004-2013, doi:10.1194/jlr.M800608-JLR200 (2009).

- 18 Swales, K. E. *et al.* Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. *Cardiovascular research* **93**, 674-681 (2011).
- 19 Ray, D. M. *et al.* Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. *Thrombosis and haemostasis* **99**, 86-95, doi:10.1160/th07-05-0328 (2008).
- 20 Evans, R. M. & Mangelsdorf, D. J. Nuclear Receptors, RXR & the Big Bang. *Cell* **157**, 255-266, doi:10.1016/j.cell.2014.03.012 (2014).
- 21 Scheer, N., Ross, J., Kapelyukh, Y., Rode, A. & Wolf, C. R. In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice. *Drug metabolism and disposition: the biological fate of chemicals* **38**, 1046-1053, doi:10.1124/dmd.109.031872 (2010).
- 22 Scheer, N. *et al.* A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. *The Journal of clinical investigation* **118**, 3228-3239, doi:10.1172/jci35483 (2008).
- 23 Ma, X. *et al.* The Pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. *Drug metabolism and disposition: the biological fate of chemicals* **35**, 194-200, doi:10.1124/dmd.106.012831 (2007).
- 24 Xie, W. *et al.* Humanized xenobiotic response in mice expressing nuclear receptor SXR. *Nature* **406**, 435-439, doi:10.1038/35019116 (2000).
- 25 Dejana, E., Quintana, A., Callioni, A. & de Gaetano, G. Bleeding time in laboratory animals. III - Do tail bleeding times in rats only measure a platelet defect? (The aspirin puzzle). *Thrombosis Research* **15**, 199-207, doi:https://doi.org/10.1016/0049-3848(79)90065-3 (1979).
- 26 Vaezzadeh, N., Ni, R., Kim, P. Y., Weitz, J. I. & Gross, P. L. Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. *Thrombosis and haemostasis* **112**, 412-418, doi:10.1160/th13-11-0919 (2014).
- 27 Greene, T. K., Schiviz, A., Hoellriegl, W., Poncz, M. & Muchitsch, E. M. Towards a standardization of the murine tail bleeding model. *Journal of thrombosis and haemostasis : JTH* **8**, 2820-2822, doi:10.1111/j.1538-7836.2010.04084.x (2010).
- 28 Watson, S., Auger, J., McCarty, O. & Pearce, A. GPVI and integrin $\alpha\text{IIb}\beta\text{3}$ signaling in platelets. *Journal of Thrombosis and Haemostasis* **3**, 1752-1762 (2005).
- 29 Senis, Y. A., Mazharian, A. & Mori, J. Src family kinases: at the forefront of platelet activation. *Blood* **124**, 2013-2024 (2014).
- 30 Bye, A. P. *et al.* Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. *Blood Advances* **1**, 2610-2623, doi:10.1182/bloodadvances.2017011999 (2017).
- 31 Futami, M. *et al.* G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase. *Blood* **118**, 1077-1086, doi:10.1182/blood-2009-12-261636 (2011).
- 32 Vaiyapuri, S., Flora, G. D. & Gibbins, J. M. Gap junctions and connexin hemichannels in the regulation of haemostasis and thrombosis. *Biochemical Society transactions* **43**, 489-494, doi:10.1042/bst20150055 (2015).
- 33 Metharom, P., Berndt, M. C., Baker, R. I. & Andrews, R. K. Current State and Novel Approaches of Antiplatelet Therapy Significance. *Arteriosclerosis, thrombosis, and vascular biology* **35**, 1327-1338 (2015).
- 34 Flora, G. D. & Nayak, M. K. A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. *Current pharmaceutical design*, doi:10.2174/1381612825666190925163827 (2019).
- 35 Unsworth, A. J., Flora, G. D. & Gibbins, J. M. Non-genomic effects of nuclear receptors: insights from the anucleate platelet. *Cardiovasc Res* **114**, 645-655, doi:10.1093/cvr/cvy044 (2018).
- 36 Iyer, M., Reschly, E. J. & Krasowski, M. D. Functional evolution of the pregnane X receptor. *Expert Opin Drug Metab Toxicol* **2**, 381-397, doi:10.1517/17425255.2.3.381 (2006).

- 37 Jones, S. A. *et al.* The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. *Molecular Endocrinology* **14**, 27-39 (2000).
- 38 Moore, J. T. & Kliewer, S. A. Use of the nuclear receptor PXR to predict drug interactions. *Toxicology* **153**, 1-10 (2000).
- 39 Bishop-Bailey, D. The platelet as a model system for the acute actions of nuclear receptors. *Steroids* **75**, 570-575, doi:<https://doi.org/10.1016/j.steroids.2009.09.005> (2010).
- 40 Ruslami, R. *et al.* Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. *Antimicrobial agents and chemotherapy* **51**, 2546-2551 (2007).
- 41 Seth, V. *et al.* Serum concentrations of rifampicin and isoniazid in tuberculosis. *Indian pediatrics* **30**, 1091-1098 (1993).
- 42 van Ingen, J. *et al.* Why do we use 600 mg of rifampicin in tuberculosis treatment? *Clinical Infectious Diseases* **52**, e194-e199 (2011).
- 43 Rowley, J. W., Schwertz, H. & Weyrich, A. S. Platelet mRNA: the meaning behind the message. *Current opinion in hematology* **19**, 385-391, doi:10.1097/MOH.0b013e328357010e (2012).
- 44 Schwertz, H., Rowley, J. W., Zimmerman, G. A., Weyrich, A. S. & Rondina, M. T. Retinoic acid receptor- α regulates synthetic events in human platelets. *Journal of Thrombosis and Haemostasis* **15**, 2408-2418 (2017).
- 45 Xu, B. & Koenig, R. J. An RNA-binding domain in the thyroid hormone receptor enhances transcriptional activation. *Journal of Biological Chemistry* **279**, 33051-33056 (2004).
- 46 Ottaviani, S., de Giorgio, A., Harding, V., Stebbing, J. & Castellano, L. Noncoding RNAs and the control of hormonal signaling via nuclear receptor regulation. *Journal of molecular endocrinology* **53**, R61-R70 (2014).
- 47 Ali, F. Y., Hall, M. G., Desvergne, B., Warner, T. D. & Mitchell, J. A. PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha--brief report. *Arterioscler Thromb Vasc Biol* **29**, 1871-1873, doi:10.1161/ATVBAHA.109.193367 (2009).
- 48 Watkins, R. E. *et al.* The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. *Science (New York, N.Y.)* **292**, 2329-2333, doi:10.1126/science.1060762 (2001).
- 49 Flora, G. D. *Non-genomic effects of the Pregnane X Receptor (PXR) and Retinoid X Receptor (RXR) in platelets.* PhD thesis, University of Reading, (2018).

Acknowledgements

This work was supported by a Felix Scholarship (2014-17), Saudi cultural bureau (London), British Heart Foundation (RG/09/011/28094 and RG/15/2/31224), the Medical Research Council (MR/J002666/1) and Biotechnology and Biological Sciences Research Council. The main part of this work has been previously published as a PhD thesis by the University of Reading (UoR) institutional repository - Central Archive at the University of Reading (CentAUR)⁴⁹. The initial publication on CentAUR does not legally preclude further publication of the document in scientific journals.

Author Contributions

G.D.F. and K.A.S. designed the research, performed experiments, analysed results and wrote the article. P.S., L.M.H., S.K.A., and A.R.S. performed experiments and analysed results. M.C., T.S. and A.J.U. performed experiments. J.M.G. designed the research and wrote the article.

Competing Interests: The authors declare no competing interests .

FIGURE LEGENDS

Figure 1. PXR is present in human platelets. (A) PXR was immunoprecipitated (IP: PXR) from human platelets (IP: PXR) using a mouse monoclonal antibody and blotted with a rabbit polyclonal antibody. Human whole platelet lysates (WPL) and antibody used to IP (Ab: PXR) PXR were used as positive and negative controls, respectively. Cropped western blot image is representative of 3 separate experiments using different donors. Full length blot is shown in supplementary figure 8A (B) The localisation of PXR in human resting platelets was investigated using immunofluorescence microscopy. PXR (in red) and membrane GPIb receptors (in green) were stained using anti-PXR and anti-GPIb antibodies. Platelets without primary antibody treatment were used as negative controls. (C) Flow cytometry was used to examine the median fluorescence level of PXR in permeabilised resting and activated (with 0.1 U/ml thrombin) human platelets, incubated with a PXR antibody or the equivalent rabbit IgG isotype control. (D) Median fluorescence intensity (MFI) associated with the PXR positive platelets in resting and activated platelets. Data represent mean \pm SD (N \geq 3), *P<0.05 was calculated by Student T-test. Figure adapted from corresponding PhD thesis⁴⁹.

Figure 2. PXR and RXR interact and co-localise in human platelets. (A) RXR was immunoprecipitated from human washed platelets (8×10^8 cells/ml) using a mouse monoclonal anti-RXR antibody. Immunoblot analysis was followed with the addition of a rabbit polyclonal anti-PXR antibody and its detection using a secondary antibody that does not recognize denatured IgG. The presence of RXR was also confirmed in the same samples. Cropped representative blot of 3 separate experiments is shown. Full length blot of PXR and RXR is shown in supplementary figure 8Bi and 8Bii respectively (B) Localisation of PXR and RXR in resting and activated (with 5 μ M U46619 in the presence of integrilin) permeabilised human platelets was investigated using immunofluorescence microscopy. RXR (in red), PXR (in blue) and membrane GPIb receptors (in green) were stained using anti-RXR, anti-PXR and anti-GPIb antibodies respectively. Representative figures show the distribution of RXR and PXR in resting and activated platelets. (C) Scatter plots between the fluorescence intensity points of RXR and PXR in resting and activated platelets represent the degree of colocalisation between RXR and PXR. (D) The Pearson correlation coefficient (PCC) representing the degree of colocalisation between RXR-PXR in resting and activated platelets. PCC was quantified for 12 platelets using different fields. Data represent mean \pm SD, **P<0.01 and ***P<0.001 was calculated by Student T-test. Figure adapted from corresponding PhD thesis⁴⁹.

Figure 3. SR12813 inhibits platelet aggregation, integrin α IIb β 3 activation and secretion. Human washed platelets (4×10^8 cells/ml) pre-treated with SR12813 or vehicle-control (DMSO, 0.1% v/v) were stimulated with (A, B) collagen (EC₅₀: 0.5-0.8 μ g/ml) or (C) thrombin (EC₅₀: 0.03-0.04 U/ml). Representative aggregation traces are shown. Quantified data displays the percentage of aggregation (vehicle-treated samples represent 100% aggregation) at the end of 5 minutes. (D) Human PRP treated with SR12813 or vehicle for 10 minutes was

stimulated with CRP-XL (EC₅₀: 0.25 µg/ml) or thrombin (EC₅₀: 0.05 U/ml) and fibrinogen binding to integrin αIIbβ3 was measured using flow cytometry. **(E)** P-selectin exposure was measured in SR12813 treated PRP, stimulated with CRP-XL (0.25 µg/ml) or thrombin (0.05 U/ml). Vehicle-treated control is defined as 100% fibrinogen binding and P-selectin exposure. ATP release was monitored for 5 minutes in washed platelets (4x10⁸ cells/ml), incubated with SR12813 or vehicle-control for 20 mins and stimulated with **(F)** collagen (1 µg/ml) or **(G)** thrombin (0.05 U/ml). Representative traces and quantified data are shown. Vehicle-treated samples represent 100% ATP secretion. **(H)** TxB₂ production was evaluated in human washed platelets (4x10⁸ cells/ml) pre-incubated with SR12813 or vehicle control for 20 min and stimulated by CRP-XL (1 µg/ml) or thrombin (0.05 U/ml) for 5 minutes. Data represent mean±SD (n≥3), *P<0.05, **P<0.01 and ***P<0.001 was calculated by one-way ANOVA. Figure adapted from corresponding PhD thesis⁴⁹.

Figure 4. PXR ligands function in a species-specific manner and inhibit thrombus formation *in vitro*. Human or mouse PRP was treated with **(A)** SR12813 or **(B)** PCN or vehicle-control (0.1% DMSO v/v for SR12813 or 0.5% v/v DMSO for PCN) prior to stimulation with CRP-XL (0.25 µg/ml for human platelets and 0.5 µg/ml for mouse platelets). The level of fibrinogen binding to integrin αIIbβ3 was measured using flow cytometry. Human or mouse blood, incubated with DiOC6 (5 µM) were perfused through collagen-coated (100 µg/ml) microfluidic chips at arterial flow rate (20 dyne/cm²) after treatment with **(C, D)** SR12813 or **(E, F)** PCN or vehicle-control (0.1% DMSO v/v for SR12813 or 0.5% v/v DMSO for PCN) for 20 minutes. Representative images display thrombus formation. Quantified data represent mean thrombus fluorescence intensity normalised to fluorescence level of the vehicle-treated sample obtained at the end of the assay. Data represent mean±SD (n≥3) where *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 was determined by student t-test or one-way ANOVA for fibrinogen binding assay and two-way ANOVA for *in vitro* thrombus formation assay. Figure adapted from corresponding PhD thesis⁴⁹.





Figure 5. SR12813 inhibit thrombosis and haemostasis. Laser-induced injury model was used to measure thrombosis in hPXR mice through intravital microscopy. Vehicle-control (DMSO 0.1% v/v) or SR12813 (100 µM) was administered intravenously to mice and incubated for 20 minutes. Platelets were labelled with Alexa488-conjugated anti-GPIb antibody. **(A)** Representative images of thrombi obtained at different time intervals. **(B)** Data represent median fluorescence intensity, measured for 8 to 10 thrombi from 3 mice each of control and SR12813 treated groups. **(C)** Thrombus-size was calculated using area under the median fluorescence intensity curve of each thrombi. **(D)** Mean of maximum fluorescence intensity of the thrombus. **(E)** Tail bleeding was performed on hPXR mice pre-treated with vehicle or SR12813 (100 µM) for 20 min (n=7). Data represent mean ± SD (n≥3) where *P<0.05, **P<0.01 and ***P<0.001 was determined by nonparametric Mann-Whitney U test. Figure adapted from corresponding PhD thesis⁴⁹.

Figure 6. SR12813 inhibit outside-in signalling in platelets. Human washed platelets (2×10^7 cells/ml) were treated with SR12813 (50 and 100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 minutes and added onto **(A)** fibrinogen (100 $\mu\text{g}/\text{ml}$) or **(C)** collagen-coated coverslips for 45 mins. Platelets were stained using Alexa-Fluor 488 for visualisation using a Nikon A1-R confocal microscope (100X). 5 images were captured of each sample at random locations. Representative images of platelet adhesion and spreading are shown. Cumulative data of platelets adhered in each sample is shown. Spreading platelets were divided into 3 classes: (adhered but not spread; filopodia: spreading platelets and lamellipodia: fully spread). Results expressed (as relative frequency) as the percentage of the total number of platelets adhered. **(B)** Human PRP was incubated with SR12813 (20, 50 and 100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 minutes. Extent of clot retraction was determined by comparing clot weight after 60 minutes. Representative image of clot retraction after the end of the assay is shown. Cumulative data represent clot weight (in mg) of samples treated with SR12813 compared with vehicle-control. Data represent mean \pm SD ($n \geq 3$), * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$ was calculated by one-way ANOVA. Figure adapted from corresponding PhD thesis⁴⁹.


Figure 7. SR12813 negatively regulate GPVI-mediated signalling. Platelets (4×10^8 cells/ml) were pre-treated with vehicle (DMSO 0.1% v/v) or SR12813 (0, 50 and 100 μM) for 20 minutes and stimulated with CRP-XL (1 $\mu\text{g}/\text{ml}$) for 90 seconds in the presence of indomethacin (20 μM), cangrelor (1 μM), MRS2179 (100 μM) and EGTA (1 mM). Samples were tested for **(A)** Total tyrosine, **(B)** Syk (Y525/526), **(C)** LAT (Y200), **(D)** PLC γ 2 (Y1217) and **(F)** PKC substrate phosphorylation. Representative immunoblots are shown. Levels of phosphorylation were quantified and expressed as a percentage of untreated (vehicle) controls. 14-3-3- ζ or actin was used as a loading control. Full length blots are shown in supplementary figure 9 **(E)** Calcium mobilisation was evaluated in Fura-2AM loaded platelets (4×10^8 cells/ml) incubated with SR12813 (50 and 100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 min prior to stimulation with CRP-XL (0.25 $\mu\text{g}/\text{ml}$). Traces of CRP-XL-stimulated calcium mobilisation over a period of 5 minutes are shown. Cumulative data (peak calcium levels) of calcium mobilisation. Data represent mean \pm SD ($n \geq 3$) where * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ and **** $P < 0.0001$ was determined by One-way ANOVA. Figure adapted from corresponding PhD thesis⁴⁹.

Figure 8. SR12813 inhibit tyrosine phosphorylation of SFKs proximal to GPVI, CLEC-2 and integrin $\alpha\text{IIb}\beta 3$ receptors. Platelets (4×10^8 cells/ml) were pre-treated with vehicle-control (DMSO 0.1% v/v) or SR12813 (0, 50 and 100 μM) for 20 minutes and stimulated for **(A, B)** 90 seconds with CRP-XL (1 $\mu\text{g}/\text{ml}$) or **(C)** 120 seconds with rhodocytin (100 nM) in the presence of indomethacin (20 μM), cangrelor (1 μM), MRS2179 (100 μM) and EGTA (1 mM). **(D)** Washed platelets (4×10^8 cells/ml), pre-treated with SR12813 (0, 50 and 100 μM) or vehicle-control were exposed to fibrinogen-coated wells (100 $\mu\text{g}/\text{ml}$) of a tissue culture plate and allowed to adhere for 30 minutes. Samples were tested for Src (Y418) or Lyn (Y396)

phosphorylation. Representative immunoblots are shown. The phosphorylation levels were quantified and expressed as a percentage of untreated (vehicle) controls. Actin was used as a loading control. Full length blots are shown in supplementary figure 9 and 10. Results are mean \pm SD (n \geq 3), *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 was calculated by one-way ANOVA. Figure adapted from corresponding PhD thesis⁴⁹.




A




B Resting platelets


Activated platelets





C





D

















Supplementary Information

Non-genomic effects of the Pregnane X Receptor negatively regulate platelet functions, thrombosis and haemostasis

Gagan D. Flora^{1, 2 †}, Khaled A. Sahli^{1 †}, Parvathy Sasikumar^{1,3}, Lisa-Marie Holbrook^{1,4}, Alexander R. Stainer¹, Sarah K. Alouda¹, Marilena Crescente^{1,5}, Tanya Sage¹, Amanda J. Unsworth^{1,6} and Jonathan M. Gibbins¹

¹Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, UK

²Department of Internal Medicine, University of Iowa, Iowa City, IA, USA

³Centre for Haematology, Imperial College London, London, UK

⁴School of Cardiovascular Medicine and Sciences, King's College London, London, UK

⁵Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

⁶School of Healthcare Science, Manchester Metropolitan University, Manchester, UK

Methods

Human platelet preparation

Human blood was taken from consenting, drug-free volunteers on the day of the experiment according to the methodology approved by the University of Reading Research Ethics Committee. Blood was taken using 3.8% (w/v) sodium citrate and Acid Citrate Dextrose (ACD; 110 mmol/L glucose, 80 mmol/L citric acid, 120 mmol/L sodium citrate) as an anticoagulant. Whole blood was centrifuged at 102*g* for 20 minutes at 20°C to yield platelet-rich plasma (PRP). Where washed platelets were required, they were isolated from the PRP by further centrifugation at 1413*g* for 10 minutes at 20°C in the presence of 0.1 µg/ml prostacyclin to prevent activation. The supernatant was discarded in Klorsept disinfectant (Medentech, Wexford, Ireland) and the platelet pellet was resuspended in 25ml of modified Tyrodes-HEPES buffer (134 mmol/L NaCl, 0.34 mmol/L Na₂HPO₄, 2.9 mmol/L KCl, 12 mmol/L NaHCO₃, 20 mmol/L HEPES, 5 mmol/L glucose, 1 mmol/L MgCl₂, pH 7.3) and 3 ml of ACD in the presence of 0.1 µg/ml prostacyclin. Platelets were centrifuged at 1413*g* for 10 minutes at 20°C and resuspended to a density of 4x10⁸ cells/ml in modified Tyrodes-HEPES buffer using a platelet count obtained with a Z Series Coulter Counter (Beckman Coulter, CA, USA). Washed platelets were rested for at least 30 minutes at 30°C prior to the experiment to allow responses to recover. Platelet preparations typically contained fewer than 1 contaminating erythrocyte or leukocyte per 6500 platelets.

ADP-sensitive washed platelets were prepared by collecting blood into 3.8% (w/v) sodium citrate and centrifugation at 102*g* for 20 minutes at 20°C to yield PRP (without the addition of ACD). Platelets were isolated from the PRP by further centrifugation at 350*g* for 20 minutes. The supernatant was discarded, and the platelet pellet was resuspended to a density of 4x10⁸ cells/ml in modified Tyrodes-HEPES buffer.

Immunofluorescence microscopy

Human blood was collected in vacutainers containing sodium citrate as described previously. The blood was centrifuged at 100*g* for 20 minutes to collect PRP. Resting or activated platelets (stimulated with 5 µM U46619; in the presence of 4 µM integrillin) in PRP were fixed with an equal volume of 8% paraformaldehyde-PBS (PFA-PBS) to make a final concentration of 4% (v/v) and incubated for 15 min. Thereafter, platelets were centrifuged at 950*g* for 10 minutes. The supernatant was removed, and platelet pellet was resuspended in 2 ml of PBS-ACD (pH 6.1) for washing. Platelets were centrifuged for 10 minutes at 950*g* and resuspended in 1 ml of PBS-ACD to concentrate platelets. Platelets were centrifuged again at the same speed for 10 minutes and then resuspended in 500µl of 1% (w/v) BSA-PBS, to concentrate platelets even more. Poly-L-lysine coated-12mm coverslips (VWR micro cover glass No.1.5) were put in 6x6 culture plate and 90µl of platelets were added on each coverslip. Culture plates were placed at 37°C for 90

minutes. After 2-3 washes with PBS, samples were blocked with 0.2% (v/v) Triton-X-100, 2% (v/v) serum from same species as secondary antibody and 1% (w/v) protease-free BSA for 1h. Thereafter, anti-PXR and anti-GPIb primary antibodies diluted (1:100) in 0.2% (v/v) Triton-X-100, 2% (v/v) serum from the same species as secondary antibody and 1% (w/v) protease-free BSA were added and left overnight. The following day, samples were washed with PBS (2-3 times) and secondary antibodies (1:200) were added for 1 hour at room temperature. The unbound antibodies were washed off with PBS (2-3 times) and samples were fixed using 4% (v/v) PFA-PBS for 5 minutes. The coverslips were washed again with PBS (2-3 times). Coverslips were placed on glass slides after adding ProLong Gold Antifade mounting media (Life technologies). The slides were kept at room temperature until mounting media dried and then kept in the fridge until they were imaged using a Nikon A1-R confocal microscope (100x oil immersion).

Platelet aggregometry

Light transmission aggregometry (LTA) was performed in an optical platelet aggregometer (Chrono-Log, PA, USA, and Helena Biosciences Europe, Gateshead, UK). Washed platelets (4×10^8 cells/ml) were stimulated in the presence of agonist (collagen, CRP-XL, thrombin, U46619 or ADP) with continuous stirring (1200 rpm at 37°C) for 5 minutes and aggregation was measured as an increase in light transmittance. The effects of PXR ligands on platelet aggregation were measured by incubating washed platelets with PXR ligand dissolved in DMSO (final DMSO concentration in sample of 0.1% v/v) or vehicle control (containing, DMSO 0.1% v/v) for 10 or 20 minutes prior to the addition of agonist. The data was quantified by considering vehicle-treated samples as 100% aggregation and the level of aggregation obtained in PXR treated samples was normalised to it.

Fibrinogen binding and alpha granule secretion

Fibrinogen binding and P-Selectin exposure were measured using FITC-conjugated polyclonal rabbit anti-human fibrinogen antibody and PE/Cy5 mouse anti-human CD62P antibody, respectively, in a 96-well flat bottom plate. PRP was treated with PXR ligands or vehicle control for 10 minutes (containing, DMSO 0.1% v/v). 1 μ l each of anti-fibrinogen and anti-CD62P antibody was added per 50 μ l sample prior to stimulation with agonists (CRP-XL or thrombin) for 20 minutes with occasional gentle mixing. GPRP (25 μ g/ml) was added in samples stimulated with thrombin to prevent fibrin polymerization. Reactions were stopped by adding 0.2% (w/v) formyl saline. Analyses were performed by flow cytometry using a BD Accuri C6 flow cytometer (BD Biosciences, Oxford, UK), and data were collected from 10,000 events [gated on platelets using FSC (forward scatter, limited between 1520-16000000) and SSC (side scatter, limited between 152-1600000)] and analysed using inbuilt BD Accuri C6 plus software, version 1.0.264.21.

Measurement of PXR in platelets using flow cytometry

To measure PXR within platelets, resting and activated (with 1 µg/ml CRP-XL in the presence of integrilin) human washed platelets (200 µl) at 4×10^8 cells/mL were fixed by adding an equal volume 2% (w/v) formal saline and permeabilised using 400 µl of BD Phosflow Perm Buffer III (BD Bioscience, Oxford, UK) for 1 h in ice. Platelets were then incubated with rabbit anti-PXR primary antibody (SantaCruz; sc-25381) for an hour. Following washing at 550g for 20 min, platelets were resuspended in HEPES buffer saline. Thereafter, platelets were incubated with an appropriate secondary Cy5-conjugated antibody (Invitrogen, Paisley UK) for an hour. Negative controls were set using an appropriate isotype control. Analyses were performed by flow cytometry using a BD Accuri C6 flow cytometer (BD Biosciences, Oxford, UK), and data were collected from 10,000 events [gated on platelets using FSC (forward scatter, limited between 1520-16000000) and SSC (side scatter, limited between 152-1600000)] and analysed using inbuilt BD Accuri C6 plus software, version 1.0.264.21.

Dense granule secretion

Secretion of ATP from dense Granule upon platelet agonist stimulation was measured in washed platelets (4×10^8 cells/ml) using a Lumi-aggregometer (model 700, Chrono-Log, PA, USA) (Feinman et al., 1977). Washed platelets were added to a glass cuvette and incubated with the Chronolume reagent for 2 minutes, while stirring using the aggregometer. 2 nM ATP was added to this stirred suspension of platelets to set the ATP response baseline. The luminescence increase was observed using the AggroLink 8 software (Chrono-Log, PA, USA), with the luminescent gain adjusted until the ATP response was within the manufacturer-instructed range of 20-60%. These settings were saved and used for the rest of the experiment. Thereafter, washed platelets were incubated with PXR ligands or vehicle control (containing, DMSO 0.1% v/v) at 37°C for 20 minutes under non-stirring conditions. 2 minutes prior the end of incubation period, Chronolume reagent was added and stirred using the aggregometer. Washed platelets were then stimulated by the addition of agonist (collagen or thrombin) and the baseline was set. ATP release from dense granule was recorded for 5 minutes following the addition of agonist using the AggroLink 8 software, which calculates ATP secretion levels from the 2nM ATP standard.

Measurement of intracellular calcium mobilisation

PRP was incubated with Dual excitation dye (at 340 and 380 nm), Fura-2AM (2 μ M) for 1 hour at 30°C and was followed by centrifugation at 350g for 20 minutes. The platelet pellet was resuspended in modified Tyrodes-HEPES buffer (4×10^8 cells/ml). Thereafter, Fura-2 AM loaded washed platelets were incubated with PXR ligands or vehicle control (containing, DMSO 0.1% v/v) for 10 minutes at 37°C prior to addition of platelet agonists (CRP-XL or thrombin). Fluorescence measurements (excitation 340 and 380 nm, emission 510 nm) were recorded for 5 minutes (1 measurement every 1.5s) using a NOVostar plate reader. $[Ca^{2+}]_i$ was estimated by using the ratio of the 340 nm and 380 nm excited signals. Calibration was performed by treating an untreated sample with digitonin (50 μ M) to lyse the platelets, which releases the Fura-2AM into the Tyrodes buffer, containing $CaCl_2$ (2 mM), allowing measurement of the maximum fluorescence ratio. To calculate the minimum fluorescence ratio, Ca^{2+} ions were chelated by addition of 10 mM ethylene glycol-bis(β -aminoethyl ester)-N,N,N',N'-tetraacetic acid (EGTA) and 10 mM TRIS base (added to ensure an alkaline pH for optimal Ca^{2+} buffering by EGTA). Auto-fluorescence was measured using unloaded platelets. Using these calibration values (maximum, minimum and autofluorescence), experimental $[Ca^{2+}]_i$ concentrations were calculated using the following equation:

$$[Ca^{2+}]_i = K_d \times \frac{S_f}{S_b} \times \frac{R - R_{min}}{R_{max} - R}$$

Where K_d is the dissociation constant of Fura-2AM (~224 nM). S_f and S_b are the values of the fluorescence at 380nm excitation (corrected to background auto-fluorescence), with zero or saturating $[Ca]^{2+}$ respectively. R is the 340/380nm fluorescence ratio, corrected for background fluorescence. R_{min} and R_{max} are the ratio limits at zero or saturating $[Ca]^{2+}$, respectively, adjusted using a viscosity constant of 0.85. This corrects for the effects of the cellular environment on the fluorescence of Fura-2.

Platelet adhesion and spreading

Glass coverslips were placed in 6 well plates and coated with collagen or fibrinogen (100 μ g/ml each) (in modified PBS) for 1 hour. 1% (w/v) BSA was then added onto coverslips and incubated for 1 hour to prevent platelets binding to the glass. The coverslips were washed 3 times with PBS. Washed platelets at a density of 2×10^7 cells/ml were treated with PXR ligand or vehicle control (containing, DMSO 0.1% v/v) for 20 minutes, and then added onto coverslips and incubated for 45 minutes at 37°C. The supernatant was then removed from the coverslips, which were again washed 3 times with PBS. Platelets were then fixed with 0.2% (w/v) paraformaldehyde (PFA) for 10 minutes, the supernatant removed, and coverslips washed 3 times with PBS. Platelets were then permeabilised with 0.2% (v/v) Triton-X-100 for 5 minutes, and then the supernatant was removed and coverslips washed 3 times again with PBS. Alexa-Fluor 488 phalloidin was then added

onto the coverslips for 1 hour, incubated in the dark, to label platelet F (filamentous) actin. The supernatant was removed, and coverslips washed 3 times with PBS. Coverslips were then mounted onto slides with the addition of Prolong Gold Antifade mounting media to preserve fluorescence. Samples were imaged, using a 100X oil immersion lens on a Nikon A1-R confocal microscope (Nikon, Tokyo, Japan). Fluorescence was excited at 488 nm with an argon laser and emitted at 500-520 nm, with images captured in one focal plane. Platelet adhesion data were obtained by counting the number of platelets on 5 images of each coverslip that were captured randomly. Platelets were scored as adhered (not spread), spreading (defined as extending filopodia) or spread fully (lamellipodia formed), and the relative frequency of each population was determined using ImageJ software.

Clot retraction

The PRP was obtained as described earlier and was incubated with 2 μ l of PXR ligands or vehicle control (containing, DMSO 0.1% v/v) for 20 minutes. Modified Tyrodes-HEPES buffer was added to test tubes, along with red blood cells, to allow visualization of the clot. This was followed by the addition of PRP treated with PXR ligand or vehicle control. Clot formation was initiated by adding thrombin (final concentration 1 U/ml) to the test tubes. A glass pipette was added to the centre of each test tube, around which the clot would form, and samples were placed in an incubator chamber at 37°C. Photographs were taken every 10 minutes and the assay was terminated after 60 minutes at which time the clot in the vehicle-treated samples were seen to have retracted completely. Clot weight was measured as a marker for clot retraction. Clots were removed from the glass pipettes and transferred into the pre-weighed microfuge tubes. Clot mass was determined by subtracting the weight of pre-weighed microfuge tubes from the weight of microfuge tubes containing clot.

Western blotting

Human washed platelets were prepared at a density of 8×10^8 cells/ml as described earlier and lysed by adding 6X Laemmli sample reducing buffer [4% (w/v) SDS, 20% (v/v) glycerol, 0.5M Tris, 0.001% (w/v) Brilliant Blue R and 10% (v/v) 2-mercaptoethanol]. Samples were heated to 95°C for 5 minutes before storing at -20°C until use.

To study cell signalling, human washed platelets were prepared at a density of 4×10^8 cells/ml under non-aggregation conditions [indomethacin (20 μ M), cangrelor (1 μ M), MRS2179 (100 μ M) and EGTA (1 mM)]. These platelets were treated with PXR ligands or vehicle control (containing DMSO, 0.1% v/v) for 20 minutes and then stimulated with platelet agonists in the aggregometer. Unstimulated or stimulated samples were lysed

with 6X Laemmli sample reducing buffer and heated to 95°C for 5 minutes before storing at -20°C until use.

Proteins were separated by SDS-PAGE as described previously by Laemmli (1970), using 10% or 4-20% Mini-PROTEAN TGX precast protein gels. Samples were heated to 95°C for 5 minutes again prior to loading into gels, which were submerged in 1X Tris/Glycine/SDS buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) within a Mini-PROTEAN tetra vertical electrophoresis cell (Bio-Rad, CA, USA). Electrophoresis was run for 45 minutes or 1 hour at a constant voltage of 150V.

The separated proteins on gels were transferred to a polyvinylidene difluoride (PVDF) membrane using semi-dry western blotting (Trans-Blot SD Semi-Dry Transfer Cell; BioRad, CA, USA). A single piece of PVDF membrane soaked in methanol was placed below the resolving gel in the transfer cell. This arrangement of gel and PVDF membrane was sandwiched between 4 sheets of 3MM filter paper soaked in cathode buffer (25 mM Tris-base, 40 mM 6-amino-N-hexanoic acid; pH 9.4) placed at the top and 4 sheets of 3MM filter paper soaked in anode buffer (300 mM Tris-base, 20% (v/v) methanol; pH 10.4) placed at the bottom. A constant voltage of 15V was applied to this setup for 2 hours to facilitate efficient transfer of proteins from gel to membrane.

PVDF membranes were then transferred into a 5% (w/v) solution of bovine serum albumin (BSA) dissolved in Tris-buffered saline with Tween 20 (TBS-T) (20 mM Tris, 140 mM NaCl, 0.1% Tween, pH 7.6) to block the membrane for 1 hour at room temperature. Primary antibodies were added into a 2% (w/v) solution of BSA (dissolved in TBS-T) and membranes were incubated with these solutions overnight at 4°C on a rotator. Primary antibody solutions were removed from the PVDF membranes the next day and membranes were washed three times for 10 minutes each with TBS-T. Secondary antibodies were added to a 2% (w/v) BSA (dissolved in TBS-T) solution, which was then added to PVDF membranes and incubated in the dark at room temperature for 1 hour. PVDF membranes were washed three times again for 5 minutes each with TBS-T. PVDF membranes were scanned using a Typhoon FLA 9500 (Amersham Biosciences, Buckinghamshire, UK), and quantification of the fluorescence intensity of individual bands was determined using Image Quant software version 8.1 (GE healthcare).

Immunoprecipitation

Washed human platelets were prepared (8×10^8 cells/ml) as described previously. Cells were lysed on ice using an equal volume of 2X NP40 buffer (300 mM NaCl, 20 mM Tris, 10 mM EDTA, 2% v/v NP40; pH=7.3) containing protease inhibitors [Leupeptin (10 µg/ml), aprotinin (10 µg/ml), phenylmethylsulphonyl fluoride (1 mM) sodium orthovanadate (1mM) and pepstatin-A (25 µg/ml)]. The lysed platelets in NP40 buffer

(1X) were incubated with primary antibody and Protein A/G magnetic beads (20 μ l per 500 μ l of lysate) at 4°C overnight. The following day, the beads were collected in Eppendorf tube using a magnetic stand and washed twice with NP40 buffer (1X) containing protease inhibitors and once with TBST. Thereafter, 100 μ l of 2X Laemmli sample reducing buffer was added to the beads. The samples were then heated to 95°C for 5 minutes and kept at -20°C for use in Western blotting.

***In vitro* thrombus formation under flow**

Human or mouse whole blood was incubated at 30°C with 5 μ M of the lipophilic dye DiOC6 for 1 hour. Microfluidic channels (Cellix, Dublin, Ireland) were coated with type I collagen (100 μ g/ml) for one hour and excess collagen was washed with modified Tyrodes-HEPES buffer. Whole blood was incubated with PXR ligands or vehicle control (containing, DMSO 0.1% v/v DMSO) for 20 minutes prior to perfusion through the collagen-coated microfluidic channels at an arteriolar shear stress of 20 Dyne/cm² (shear rate: 500 s⁻¹). Fluorescence was excited at 488 nm with an argon laser and emission detected at 500-520 nm. The thrombus formation on the microfluidic chip was observed using a Nikon A1-R confocal microscope with a 20X objective and images (focused on a single section) were captured every 1 second for 600 seconds. Mean thrombus fluorescence intensity was calculated using NIS Elements software (Nikon, Tokyo, Japan).

***In vivo* thrombus formation**

The mice were anaesthetised by intraperitoneal injection of ketamine (125 mg/kg), xylazine (12.5 mg/kg) and atropine (0.25 mg/kg). Anaesthesia was maintained with 5 mg/kg pentobarbital as and when required. The cremaster muscle was exteriorized and the connective tissue removed, after which an incision was made, allowing the cremaster muscle to be affixed over a glass slide as a single sheet; the muscle preparation was hydrated throughout with buffer (135mM NaCl, 4.7mM KCl, 2.7mM CaCl₂, 18mM NaHCO₃, pH 7.4). SR12813, vehicle control (containing, DMSO 0.1% v/v) and DyLight 649 anti-GPIb α antibody (0.2 μ g/g mouse weight; for platelet labelling) was infused into the mouse circulation through carotid artery cannula prior to the injury (performed using a Micropoint Ablation Laser Unit; Andor Technology PLC, Belfast, Northern Ireland). Thrombus formation was visualised after 20 minutes of the infusion of SR12813 or vehicle control using an Olympus BX61W1 microscope (Olympus Corporation, Tokyo, Japan). The images were captured both prior to and after the injury, using a Hamamatsu digital camera C9300 (Hamamatsu Photonics UK Ltd, Hertfordshire UK) charge-coupled device (CCD) camera in 640 x 480 format. Images were analysed using Slidebook 6 software (Intelligent Imaging Innovations, CO, USA). Following the procedure, mice were


sacrificed in accordance with Home office licences and approval from the University of Reading local ethics review panel and Animal welfare and Ethics Research Board.

Tail bleeding assay

On the day of the experiment, C57/BL6 or hPXR mice were anaesthetised by intraperitoneal injection of ketamine (125 mg/kg) and xylazine (12.5 mg/kg) and SR12813 or vehicle control (containing, DMSO 0.1% v/v) was injected via the femoral vein. 20 minutes later, the tail tip was removed with a scalpel and the tail was immediately placed into tubes containing saline, in a manner that prevented the cut end of the tail from contacting the side of the tube. The time of bleeding was recorded until the blood flow had ceased. Following the procedure, or after 20 minutes, mice were sacrificed in accordance with Home office licences and approval from the University of Reading local ethics review panel and Animal welfare and Ethics Research Board.


Supplementary figures

Suppl. Figure 1









Suppl. figure 1. PXR ligands inhibit platelet aggregation to a range of agonists. Human washed platelets (4×10^8 cells/ml) pre-treated with SR12813 or rifampicin or vehicle-control (DMSO, 0.1% v/v) were stimulated with **(A, B)** collagen (EC_{50} : 0.5-0.8 μ g/ml) or **(C)** thrombin (EC_{50} : 0.03-0.04 U/ml) or **(D, E)** U46619 (EC_{50} : 0.25 μ M) or **(F, G)** ADP (EC_{50} : 5-10 μ M). Aggregation was measured for 300 seconds. Representative aggregation traces are shown. Quantified data displays the percentage of aggregation of SR12813 or rifampicin treated samples (vehicle-treated samples represent 100% aggregation) at the end of 5 minutes. Data represent mean \pm SD (n \geq 3), *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 was calculated by one-way ANOVA. Figure adapted from corresponding PhD thesis - Non-genomic effects of the Pregnane X Receptor (PXR) and Retinoid X Receptor (RXR) in platelets⁴⁹.

Suppl. Figure 2




Suppl. figure 2. Rifampicin attenuate fibrinogen binding to integrin α IIb β 3 and degranulation. (A) Human PRP was treated with rifampicin or vehicle-control (DMSO 0.1% v/v) for 10 minutes prior to stimulation with CRP-XL (EC₅₀: 0.25 μ g/ml) or thrombin (EC₅₀: 0.05 U/ml) and fibrinogen binding to integrin α IIb β 3 was measured using flow cytometry. (B) P-selectin was measured in rifampicin treated PRP and stimulated with CRP-XL (0.25 μ g/ml) or thrombin (0.05 U/ml). Vehicle-treated control is defined as 100% fibrinogen binding and P-selectin exposure. (C, D) Changes in ATP release were monitored for 5 minutes in washed platelets (4x10⁸ cells/ml) incubated with rifampicin or vehicle-control for 20 mins and stimulated with collagen (1 μ g/ml) or thrombin (0.05 U/ml). Representative traces and quantified data are shown. Vehicle-treated samples represent 100% ATP secretion. (E) Washed platelets (4x10⁸ cells/ml) pre-treated with saturating concentrations of indomethacin (20 μ M) or ADP receptor antagonists - cangrelor (1 μ M) and MRS2179 (100 μ M) were stimulated with collagen (10 μ g/ml) in the presence or absence of SR12813 (100 μ M). Representative aggregation trace recorded for 5 minutes is shown. Quantified data for collagen-stimulated platelet aggregation in the presence or absence of SR12813, along with indomethacin (I+SR) or cangrelor and MRS2179 (C+M+SR) or all of them together (C+M+I+SR). 'O' signifies the sample stimulated with collagen in the absence of SR12813 and secondary mediator signalling blockers. Data represent mean \pm SD (n \geq 3), \dagger P<0.05 and $\dagger\dagger$ P<0.01 was calculated by student t-test. **P<0.01, ***P<0.001 and ****P<0.0001 was calculated by one-way ANOVA. Figure adapted from corresponding PhD thesis - Non-genomic effects of the Pregnane X Receptor (PXR) and Retinoid X Receptor (RXR) in platelets⁴⁹.

Suppl. Figure 3




Suppl. figure 3. PXR ligands inhibit thrombus formation *in vitro*. **(A)** Human blood incubated with DiOC₆ (5 μM) was perfused through collagen-coated (100 μg/ml) microfluidic chips at an arterial flow rate (20 dyne/cm²) after treatment with rifampicin or vehicle-control (DMSO 0.1% v/v) for 20 minutes. Representative images display thrombus formation. Quantified data represent mean thrombus fluorescence intensity normalised to fluorescence level of the vehicle-treated sample obtained at the end of the assay. The expression levels of **(B)** α₂β₁, **(C)** αIIbβ₃, **(D)** GPIb, and **(E)** GPVI were analysed on resting and CRP-XL-stimulated (1 μg/ml) platelets from hPXR and C57BL/6 wild-type mice by flow cytometry. Data represent mean±SD (n≥3) where **P ≤ 0.01, ***P<0.001 and ****P<0.0001 was determined by two-way ANOVA (*in vitro* thrombus formation) and Student t-test (flow cytometry). Figure adapted from corresponding PhD thesis - Non-genomic effects of the Pregnane X Receptor (PXR) and Retinoid X Receptor (RXR) in platelets⁴⁹.

Suppl. Figure 4




Suppl. figure 4. Rifampicin inhibit outside-in signalling in platelets. Human washed platelets (2×10^7 cells/ml) were treated with rifampicin (50 and 100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 minutes and added onto **(A)** fibrinogen (100 $\mu\text{g}/\text{ml}$) or **(C)** collagen-coated coverslips for 45 mins. Platelets were stained using Alexa-Fluor 488 for visualisation using a Nikon A1-R confocal microscope (100X). 5 images were captured of each sample at random locations. Representative images of platelet adhesion and spreading are shown. Cumulative data of platelets adhered in each sample is shown. Spreading platelets were divided into 3 classes: (adhered but not spread; filopodia: spreading platelets and lamellipodia: fully spread). Results expressed (as relative frequency) as the percentage of the total number of platelets adhered. **(B)** Human PRP was incubated with SR12813 (20, 50 and 100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 minutes. Extent of clot retraction was determined by comparing clot weight after 60 minutes. Representative image of clot retraction after the end of the assay is shown. Cumulative data represent clot weight (in mg) of samples treated with SR12813 compared with vehicle-control. Data represent mean \pm SD ($n \geq 3$), * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$ was calculated by one-way ANOVA. Figure adapted from corresponding PhD thesis - Non-genomic effects of the Pregnane X Receptor (PXR) and Retinoid X Receptor (RXR) in platelets⁴⁹.

Suppl. Figure 5




Suppl. figure 5. Human PXR ligands does not regulate cyclic nucleotide mediated signalling in platelets. Human washed platelets (4×10^8 cells/ml) were tested for **(A)** VASP S157 and **(B)** VASP S239 phosphorylation in samples treated with SR12813 or rifampicin (0, 50 and 100 μ M) or vehicle (DMSO 0.1% v/v) for 20 min. PGI₂ and PAPANOATE (NO donor), which upregulates the activity of PKA and PKG were included as positive controls. 14-3-3- ζ was used as a loading control. Full length blots are shown in supplementary figure 11. Representative blots from 3 different experiments are shown. Figure adapted from corresponding PhD thesis - Non-genomic effects of the Pregnane X Receptor (PXR) and Retinoid X Receptor (RXR) in platelets⁴⁹.

Suppl. Figure 6




Suppl. figure 6. Rifampicin negatively regulates GPVI-mediated signalling. Platelets (4×10^8 cells/ml) were pre-treated with vehicle (DMSO 0.1% v/v) or rifampicin (0, 50 and 100 μM) for 20 minutes and stimulated with CRP-XL (1 $\mu\text{g}/\text{ml}$) for 90 seconds in the presence of indomethacin (20 μM), cangrelor (1 μM), MRS2179 (100 μM) and EGTA (1 mM). Samples were tested for **(A)** Total tyrosine, **(B)** Syk (Y525/526), **(C)** LAT (Y200), **(D)** PLC γ 2 (Y1217) and **(F)** PKC substrate phosphorylation. Representative immunoblots are shown. Levels of phosphorylation were quantified and expressed as a percentage of untreated (vehicle) controls. 14-3-3- ζ or actin was used as a loading control. Full length blots are shown in supplementary figure 9 **(E)** Calcium mobilisation was evaluated in Fura-2AM loaded platelets (4×10^8 cells/ml) incubated with rifampicin (50 and 100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 min prior to stimulation with CRP-XL (0.25 $\mu\text{g}/\text{ml}$). Traces of CRP-XL-stimulated calcium mobilisation over a period of 5 minutes. Cumulative data (peak calcium levels) of calcium mobilisation. Data represent mean \pm SD ($n \geq 3$) where * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$ was determined by one-way ANOVA. Figure adapted from corresponding PhD thesis - Non-genomic effects of the Pregnane X Receptor (PXR) and Retinoid X Receptor (RXR) in platelets⁴⁹.

Suppl. figure 7




Suppl. figure 7. Rifampicin inhibit tyrosine phosphorylation of SFKs. Washed platelets (4×10^8 cells/ml) were pre-treated with vehicle-control (DMSO 0.1% v/v) or rifampicin (0, 50 and 100 μ M) for 20 minutes and stimulated for **(A, B)** 90 seconds with CRP-XL (1 μ g/ml) or **(E)** 120 seconds with rhodocytin (100 nM) in the presence of indomethacin (20 μ M), cangrelor (1 μ M), MRS2179 (100 μ M) and EGTA (1 mM). **(F)** Washed platelets (4×10^8 cells/ml), pre-treated with rifampicin (0, 50 and 100 μ M) or vehicle-control were exposed to fibrinogen-coated wells (100 μ g/ml) of a tissue culture plate and allowed to adhere for 30 minutes. The samples were tested for Src (Y418) or Lyn (Y396) phosphorylation. Representative blots for the phosphorylation levels are shown. The phosphorylation levels were quantified and expressed as a percentage of untreated (vehicle) controls. Actin was used as a loading control. **(C, D)** Rhodocytin (100 nM) induced platelet aggregation was measured in human washed platelets (4×10^8 cells/ml) pre-treated with SR12813 or rifampicin or vehicle-control (DMSO, 0.1% v/v). Aggregation was measured for 300 seconds. Representative aggregation traces are shown. Quantified data displays the percentage of aggregation of SR12813 or rifampicin treated samples (vehicle-treated samples represent 100% aggregation) at the end of 2 minutes, 3 minutes and 5 minutes. Full length blots are shown in supplementary figure 9 and supplementary figure 10. Results are mean \pm SD ($n \geq 3$), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ and **** $P < 0.0001$ was calculated by one-way ANOVA. Figure adapted from corresponding PhD thesis - Non-genomic effects of the Pregnane X Receptor (PXR) and Retinoid X Receptor (RXR) in platelets⁴⁹.

Suppl. figure 8




Suppl. figure 8. (A) Full blot image of figure 1A. PXR was immunoprecipitated (IP: PXR) from human platelets (IP: PXR), which was followed with a western blot analysis. Human whole platelet lysates (WPL) and antibody used to IP (Ab: PXR) PXR were used as positive and negative controls, respectively. **(Bi, Bii)** Full blot image of figure 2A. RXR was immunoprecipitated from human washed platelets. Immunoblot analysis was followed with the addition of an anti-PXR antibody and its detection using a secondary antibody that does not recognize denatured IgG. The presence of RXR was also confirmed in the same samples.

Suppl. figure 9



Suppl. figure 9. Platelets were pre-treated with vehicle (DMSO 0.1% v/v) or SR12813 (0, 50 and 100 μ M) for 20 minutes and stimulated with CRP-XL (1 μ g/ml) for 90 seconds in the presence of indomethacin (20 μ M), cangrelor (1 μ M), MRS2179 (100 μ M) and EGTA (1 mM). Samples were tested for Syk (Y525/526), LAT (Y200), PLC γ 2 (Y1217) and Src. **(A)** Full blot image of figure 7B and supplementary figure 6B. **(B)** Full blot image of figure 7C and supplementary figure 6C. **(C)** Full blot image of figure 7D. **(D)** Full blot image of supplementary figure 6D. **(E)** Full blot image of figure 8A. **(F)** Full blot image of supplementary figure 7A. Blots were reprobated with actin antibody to verify equivalent levels of protein loading.



Suppl. figure 10





Suppl. figure 10. Platelets were pre-treated with vehicle-control (DMSO 0.1% v/v) or SR12813 (0, 50 and 100 μ M) for 20 minutes and stimulated for 90 seconds with CRP-XL (1 μ g/ml) or 120 seconds with rhodocytin (100 nM) in the presence of indomethacin (20 μ M), cangrelor (1 μ M), MRS2179 (100 μ M) and EGTA (1 mM). Samples were tested for Lyn (Y396), or Src (Y418). **(A)** Full blot image of figure 8B. **(B)** Full blot image of supplementary figure 7B. **(C)** Full blot image of figure 8C. **(D)** Full blot image of supplementary figure 7E. Washed platelets, pre-treated with SR12813 (0, 50 and 100 μ M) or vehicle-control were exposed to fibrinogen-coated wells (100 μ g/ml) of a tissue culture plate and allowed to adhere for 30 minutes. Samples were tested for Src (Y418) phosphorylation. **(E)** Full blot image of figure 8D. **(F)** Full blot image of supplementary figure 7F. Blots were reprobated with actin or 14-3-3- ζ antibody to verify equivalent levels of protein loading.

Suppl. figure 11



A IB: VASP S157





B IB: VASP S157



C IB: VASP S239



D IB: VASP S239



Suppl. figure 11. Human washed platelets were tested for VASP S157 and VASP S239 phosphorylation in samples treated with SR12813 or rifampicin (0, 50 and 100 μ M) or vehicle (DMSO 0.1% v/v) for 20 min. PGI₂ and PAPANOATE (NO donor), which upregulates the activity of PKA and PKG were included as positive controls. **(A)** Full blot image of supplementary figure 5A. **(B)** Full blot image of supplementary figure 5B. **(C)** Full blot image of supplementary figure 5C. **(D)** Full blot image of supplementary figure 5D. Blots were reprobbed with 14-3-3- ζ antibody to verify equivalent levels of protein loading.